Emyria Ltd announced FY 2026 revenue of just over AUD 4 million, a 207.7% increase from AUD 1.3 million in FY 2025. Total financial resources, including other income and R&D contributions, reached about AUD 4.3 million.
The company expanded its clinical footprint from one operational clinic in FY 2025 to five by year‑end, adding sites in Perth (two), Brisbane, Mornington and a Sydney clinic slated for early 2027. Bed capacity grew from four to 18, and the number of trained clinicians rose from roughly 30 to 145. Authorized prescribers increased from six to 17. Patient volume climbed to 138 individuals treated or in treatment, up from 24 the previous year.
Emyria’s treatment model uses MDMA and psilocybin for post‑traumatic stress disorder (PTSD) and treatment‑resistant depression. Each dosing day comprises an eight‑hour session with two therapists; PTSD protocols involve three dosing days, depression two, delivered over a four‑to‑six‑week period. Revenue per dosing day averages AUD 10,000, and weekly dosing capacity is projected to reach 90 days across the five clinics, implying a potential annualised revenue of about AUD 46.8 million at full utilisation.
The Perth clinic has already achieved break‑even, with the company estimating a 9‑ to 12‑month horizon to profitability for each new site after an initial six‑month investment phase.
Shares fell 4.17% in after‑hours trading to $0.046 from $0.048, later trading at $0.05, down 2.17% from the prior close. The 52‑week range remains $0.04 to $0.08.
Executive co‑founder Greg highlighted Australia’s unique regulatory pathway that permits controlled‑substance therapies, noting the country was the first to reschedule MDMA and psilocybin from Schedule 9 to Schedule 8 in 2023. COO Marianne referenced Eli Lilly’s near‑AUD 3.8 billion acquisition of Atara Biotherapeutics as evidence of growing global momentum.
Emyria cited an addressable Australian market of roughly 1.1 million adults with major depression and 1.5 million with PTSD. Clinical data presented showed 76% of PTSD patients achieving clinically significant improvement 12 months post‑treatment, with two‑thirds no longer meeting diagnostic criteria. Early results for treatment‑resistant depression indicated improvements across depression scores, trauma scores and daily functioning.
The company also noted collaborations with the Department of Veterans’ Affairs and Medibank, and referenced regulatory oversight by the FDA and Australia’s Therapeutic Goods Administration.
